Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011

Ian Morrissey, Harald Seifert, Rafael Canton, Patrice Nordmann, Stefania Stefani, Alasdair MacGowan, Regina Janes, Daniel Knight, R. Bonnet, C. J. Soussy, R. Courcol, R. Leclercq, R. Zahar, C. Poyart, Y. Rio, W. Pfister, C. Schoerner, F. Albert, E. Jacobs, S. SchubertR. Mutters, F. J. Schmitz, F. Luzzaro, E. Manso, C. Scarparo, G. Fadda, F. Rossano, G. M. Rossolini, G. P. Gesu, M. P. Landini, L. Martínez, J. L. Pérez, C. Gimeno, Á Pascual, J. Liñares, R. Bartolomé, R. Cisterna, K. Gould, M. Dryden, M. Weinbren, A. Swann, M. Wilcox, G. Moore, J. Andrews, J. Ashby, S. Kaul

Research output: Contribution to journalArticle

Abstract

Objectives: To determine the activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci (VRE) and β-haemolytic streptococci recently isolated from acute bacterial skin and skin structure infections or bacteraemia in western Europe. Methods: Forty-one centres in Spain (8), Italy (9), Germany (8), France (8) and the UK (8) submitted 866 isolates [204 methicillin-resistant Staphylococcus aureus (MRSA), 177 methicillin-resistant coagulase-negative staphylococci (MRCoNS), 101 VRE, 193 Streptococcus agalactiae and 191 Streptococcus pyogenes] that were collected during the first 6 months of 2011. These were re-identified and susceptibilities to oritavancin and comparators were determined. Results: Oritavancin was very active against MRSA (MIC50/MIC90 0.03/0.06 mg/L), MRCoNS (0.06/0.12 mg/L), VRE (0.03/0.06 mg/L), S. agalactiae (0.03/0.06 mg/L) and S. pyogenes (0.06/0.25 mg/L). The highest oritavancin MIC observed was 0.25 mg/L (species were S. aureus, Staphylococcus epidermidis, Staphylococcus hominis, S. agalactiae, S. pyogenes and Enterococcus faecalis). Conclusions: These data from recently collected Gram-positive bacteria in western Europe confirm the potent in vitro activity of oritavancin against a wide range of resistant MRSA, MRCoNS and VRE isolates, including ones resistant to newer agents.

Original languageEnglish
Pages (from-to)164-167
Number of pages4
JournalJournal of Antimicrobial Chemotherapy
Volume68
Issue number1
DOIs
Publication statusPublished - Jan 2013

    Fingerprint

Keywords

  • Europe
  • Gram-positive bacteria
  • Lipoglycopeptides

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Morrissey, I., Seifert, H., Canton, R., Nordmann, P., Stefani, S., MacGowan, A., Janes, R., Knight, D., Bonnet, R., Soussy, C. J., Courcol, R., Leclercq, R., Zahar, R., Poyart, C., Rio, Y., Pfister, W., Schoerner, C., Albert, F., Jacobs, E., ... Kaul, S. (2013). Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and β-haemolytic streptococci collected from western European countries in 2011. Journal of Antimicrobial Chemotherapy, 68(1), 164-167. https://doi.org/10.1093/jac/dks344